Hyalgan (Sodium Hyaluronate)

Hyalgan is indicated for the symptomatic treatment of osteoarthritis in several large joints.

• Osteoarthritis of the knee.
• Osteoarthritis of the hip.
• Osteoarthritis of the shoulder.
• Adjunct to physical therapy for joint pain relief.
• May be considered when oral analgesics are insufficient.
• Used in patients who have contraindications to NSAIDs.
• May be administered before or after arthroscopic procedures to support joint lubrication.
• Considered for patients seeking a non‑surgical option to delay joint replacement.
• Can be combined with exercise programs to improve functional outcomes.
• May be repeated after a series of injections if clinical benefit wanes.

• Sodium hyaluronate in Hyalgan is a high‑molecular‑weight form of hyaluronic acid that, when injected into the joint space, integrates with the native synovial fluid. It increases the viscoelasticity and elasticity of the fluid, enhancing lubrication and shock absorption. The restored rheological properties reduce mechanical stress on cartilage and may modulate inflammatory pathways by interacting with CD44 receptors on synoviocytes, contributing to decreased cytokine activity.

Adverse reactions to intra‑articular Hyalgan are generally related to the injection procedure and the product composition.

Common

• Transient pain at the injection site.
• Swelling or effusion in the treated joint.
• Mild warmth or redness around the injection area.
• Temporary stiffness lasting a few days.

Serious

• Acute joint infection (septic arthritis).
• Allergic reaction such as urticaria or angioedema.
• Persistent severe joint inflammation.
• Rare cases of tendon rupture near the injection site.

Before using Hyalgan, clinicians should evaluate patient history and joint condition to minimize risks.

• Confirm diagnosis of osteoarthritis and rule out active joint infection.
• Assess for hypersensitivity to hyaluronic acid or any component of the formulation.
• Use aseptic technique and proper imaging guidance for accurate intra‑articular placement.
• Consider alternative therapy in patients with severe coagulopathy or on anticoagulants.
• Monitor for local reactions after each injection and document response.
• Avoid use in pregnant or breastfeeding women unless benefits outweigh potential risks.

Hyalgan may interact with other agents that affect joint health or increase infection risk, requiring careful assessment.

Avoid

• Concurrent intra‑articular corticosteroid injections within a short interval.
• Use with intra‑articular antibiotics unless infection is confirmed.
• Simultaneous administration of other viscosupplements in the same joint.
• Injection of hyaluronate into a joint previously treated with arthrocentesis within 24 hours.

Use with caution

• Systemic anticoagulants or antiplatelet drugs due to bleeding risk at injection site.
• Disease‑modifying antirheumatic drugs (DMARDs) that may alter immune response.
• High‑dose NSAIDs that could mask early signs of joint infection.
• Patients receiving biologic therapies should be observed for atypical inflammatory responses.